is Chair of the firm’s Intellectual Property Department and centers her practice on global patent prosecution and portfolio development, licensing, due diligence, and opinion work. With a background in biotechnology, chemistry and large-scale drug manufacturing, she understands the development of pharmaceuticals and medical devices, from early-stage research to FDA-approval, production and marketing. In addition to her experience in the chemical, pharmaceutical, and biotechnology industries, Dianna also has extensive experience with intellectual property issues in the shooting sports industry.
For more information or to contact Dianna, please visit her Firm Profile Page.
Artificial intelligence (AI) is everywhere, touching nearly every aspect of our daily lives, including how we work, communicate, shop, travel and more. The term “AI” is generally understood to encompass computerized systems that perform tasks ordinarily perceived as requiring some form of human intelligence. Many AI-based systems are able to recognize trends, patterns and connections, test hypotheses using available data sets, and continuously improve decision trees based on user input. As such, AI has been shown to have near endless applications, driving a surge of inventions and related patent application filings.